TAG: The role of iron in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha.

Inflammatory bowel disease (IBD) is a chronic inflammatory disease whose main forms are ulcerative colitis (UC) and Crohn's disease (CD).
the main symptoms and signs of IBD in the intestines.
, intestinal manifestations are common.
is a common intestinal manifestation of IBD, which significantly increases health care costs and negatively affects quality of life.
incidence of anaemia in IBD patients is about 20-30%, and Anaemia in IBD patients may be due to a variety of causes.
most commonly caused by iron deficiency caused by bleeding and absorption disorders.
in accordance with the European Crohn's and Colitis Organization (ECCO) guidelines, iron supplementation is recommended for all patients with iron deficiency anemia in IBD.
tumor necrosis factor-alpha (TNF-alpha) inhibitors (Invlixi monoantigen and Adamo monoantigen) are the first-line biological therapies in IBD patients, and mucosal healing is the key to treating chronic inflammatory diseases.
IBD patients had relatively little data on the effects of anti-TNF-alpha drugs on anemia or hemoglobin (Hb) levels, the study was designed to assess the effectiveness of iron supplementation in IBD patients who were first treated with anti-TNF-alpha drugs.
researchers analyzed data from 79 IBD patients treated with anti-TNF-alpha.
patients were divided into anti-TNF-alpha (n s 52) and iron-replenishing anti-TNF-alpha (n s 27) groups that were not treated with iron.
the effects on laboratory parameters, anaemia prevalence and disease activity after baseline (year 0) and 1 year.
levels of hemoglobin (Hb) increased significantly between years 0 and 1 in two groups of patients .TNF-alpha group was 12.0 to 1.8 to 13.3 to 2.0 g / d The L (p -lt;0.001) and the iron supplement group are 9.8 x 2.4 x 11.7 x 2.3 g / dL (p x 0.004) .
in subgroup analysis of severely anaemic IBD patients, iron supplementation increased the improvement of Hb levels (8.5 to 1.5-11.4 to 2.1 g / dL; p . 0.001) compared to the anti-TNF-alpha group .
of disease activity in both groups improved significantly over a one-year period compared to 0 years.
persistent anemia is significantly associated with severe anemia at baseline (p s 0.017).
in patients with IBD, anti-TNF-alpha drugs can improve the clinical symptoms of anemia, not iron supplementation.
, iron supplementation may be helpful in patients with severe anaemia in IBD.
.